Brazilian success: SynAct Pharma scores positive results with therapy for covid-19
After generating promising results in a phase II trial with the company's anti-inflammatory drug for treating covid-19, SynAct Pharma is looking into the possibility of launching phase III.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
SynAct Pharma has received encouraging results from the clinical trial which the company launched in April earlier this year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
